Statin discontinuation and intolerance: The challenge of lifelong therapy

Annals of Internal Medicine

Volumn 158, Issue 7, 2013, Pages 562-563

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AMNESIA; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EDITORIAL; HEALTH INSURANCE; HUMAN; LIVER INJURY; MEDICARE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 84875728653     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-158-7-201304020-00010     Document Type: Editorial

References (10)

1. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary pre-vention populations. J Gen Intern Med. 2004;19:638-45.
2. Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V, et al. Long-term persistence with statin treatment in a not-for-profit health mainte-nance organization: a population-based retrospective cohort study in Israel. Clin Ther. 2008;30:2167-79.
3. Degli Esposti L, Saragoni S, Batacchi P, Benemei S, Geppetti P, Sturani A, et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther. 2012;34:190-9.
4. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings. A cohort study. Ann Intern Med. 2013;158:526-34.
5. Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574-80.
6. Pittman DG, Fenton C, Chen W, Haffner S, Pendergrass M. Relation of statin nonadherence and treatment intensification. Am J Cardiol. 2012;110: 1459-63.
7. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardio-vascular disease: meta-analysis on 376, 162 patients. Am J Med. 2012;125:882-7.
8. Jung K, McBean AM, Kim JA. Comparison of statin adherence among ben-eficiaries in MA-PD plans versus PDPs. J Manag Care Pharm. 2012;18:106-15.
9. Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P, et al. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol. 2007;63: 197-203.
10. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Car-diol. 2011;27:635-62.